The monoclonal antibody technology of NewBio Therapeutics is based on hybridoma and phage display technology. Specifically, we design our strategy and combine with CRO service to screen antibody candidates via NBT’s mature and high efficient eFiSH screening protocol, and discover proprietary monoclonal antibody therapeutics or monoclonal antibodies that are suitable for developing ADCs.
Based on our monoclonal antibody generation/screening technology, we have already developed several antibody candidates and ADC products, which aim at different drug targets and in different R&D stages.